Why is dydrogesterone banned

Overview

Dydrogesterone is a synthetic progestogen medication first developed in the 1960s by Duphar (now part of Abbott Laboratories). Unlike many other progestogens derived from testosterone, dydrogesterone is structurally similar to natural progesterone, making it popular for gynecological conditions. It gained widespread use for treating menstrual disorders, endometriosis, and supporting pregnancy in cases of threatened miscarriage. However, its regulatory status varies globally. In 2013, the European Medicines Agency (EMA) recommended suspending its marketing authorization across the European Union after a review concluded there was insufficient evidence that its benefits outweighed risks, particularly for menopausal hormone therapy. This decision affected products like Duphaston and Femoston, though some EU countries maintained national approvals temporarily. Meanwhile, dydrogesterone remains approved in numerous countries including India, Australia, and many in Asia and Latin America, where it continues to be prescribed for various indications. The divergent regulatory approaches highlight ongoing debates about its safety profile and appropriate uses.

How It Works

Dydrogesterone functions as a progestogen, meaning it mimics the effects of the natural hormone progesterone in the body. It binds to progesterone receptors in tissues like the uterus, helping to regulate the menstrual cycle and maintain pregnancy. Specifically, it prepares the uterine lining for implantation and prevents it from shedding prematurely, which is why it's used to treat conditions like irregular periods or threatened miscarriage. Unlike some synthetic progestogens, dydrogesterone has minimal androgenic (masculinizing) or estrogenic effects, potentially reducing side effects like weight gain or mood changes. However, its mechanism also involves potential risks: studies have suggested it may increase the risk of venous thromboembolism (blood clots) compared to other progestogens, though data remains controversial. The EMA's 2013 review cited concerns about inadequate long-term safety data, especially for menopausal women using it in combination with estrogen. In countries where it's still approved, it's typically prescribed at doses ranging from 10-40 mg daily, depending on the condition, and is considered effective for managing symptoms like heavy bleeding or supporting early pregnancy.

Why It Matters

The regulatory status of dydrogesterone matters because it affects treatment options for millions of women worldwide. In countries where it's banned or restricted, patients and doctors must rely on alternative progestogens, which may have different side-effect profiles or costs. For example, in the EU, the suspension has led to shifts toward medications like micronized progesterone or other synthetics. In regions where it remains available, it provides a valuable tool for managing menstrual disorders and supporting fertility, particularly in cases where other treatments fail. The controversy also highlights broader issues in drug regulation: divergent international standards can create confusion, and safety decisions often depend on evolving evidence. For daily life, this means women's healthcare choices vary significantly by location, underscoring the importance of personalized medical advice and awareness of local regulations.